Skip to content
RDL Network logo
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial — Meletios A Dimopoulos (2016) | RDL Network